IASLC > International Association for the Study of Lung Cancer > Conferences & Events > Event Details
Promising Novel Approaches to Lung Caner
January 23, 2018 | Online


Much has changed in the treatment landscape of non-small cell lung cancer (NSCLC) over the last few years. Newer generations of oral drugs for patient with EGFR mutations or ALK translocations show better efficacy and safety. Immunotherapy is being integrated in every aspect of the management of this disease. Combination chemotherapy and immunotherapy has received FDA approval for frontline treatment. The challenge now is to decide what is the best treatment option for our patients and how to navigate this rapidly evolving field.

What you should expect to learn

After viewing this program attendees will be able to:

  • Recognize the status and use of novel systemic treatments for advanced stage NSCLC therapy;
  • Identify individual patient selection criteria for  specific therapies;
  • Define ongoing and planned clinical trials that are most likely will impact patient treatment in the near future.

Hossein Borghaei, MS, DO

Associate Professor
Chief, Thoracic Medical Oncology
Fox Chase Cancer Center
Philadelphia, PA


Ramaswamy Govindan, MD - Program Chair
Director, Section of Medical Oncology
Professor of Medicine
Anheuser-Busch Endowed Chair in Medical Oncology
Director, Section of Oncology

Washington University School of Medicine